betway必威登陆网址 (betway.com )学报››2022,Vol. 43››Issue (11): 851-855.DOI:10.3969/j.issn.2097-0005.2022.11.011
尹讯章(), 林毅(
), 王大海, 柏翠, 朱国豪, 常红(
)
收稿日期:
2022-07-01出版日期:
2022-11-25发布日期:
2022-12-23通讯作者:
常红作者简介:
尹讯章,硕士研究生,研究方向:儿童肾脏病,E-mail:2020026085@qdu.edu.cn
Received:
2022-07-01Online:
2022-11-25Published:
2022-12-23尹讯章, 林毅, 王大海, 柏翠, 朱国豪, 常红. 儿童Bartter综合征2例报道并文献复习[J]. betway必威登陆网址 (betway.com )学报, 2022, 43(11): 851-855.
图2病例2及其父母SLC12A1基因突变测序结果A为受检者SLC12A1基因c.1300G > T杂合突变;B为受检者SLC12A1基因c.1443C > A杂合突变;C为受检者之父SLC12A1基因c.1300G > T杂合突变;D为受检者之父SLC12A1基因c.1443C位点未见异常;E为受检者之母SLC12A1基因c.1300G位点未见异常;F为受检者之母SLC12A1基因c.1443C > A杂合突变
病例 | pH | PaCO2(mmHg) | HCO3-(mmol/L) | 碱剩余(BE)(mmol/L) |
---|---|---|---|---|
病例1 | 7.48 | 32 | 23.8 | 0.3 |
病例2 | 7.44 | 36 | 24.5 | 0.3 |
表12例Bartter综合征患儿血气分析结果
病例 | pH | PaCO2(mmHg) | HCO3-(mmol/L) | 碱剩余(BE)(mmol/L) |
---|---|---|---|---|
病例1 | 7.48 | 32 | 23.8 | 0.3 |
病例2 | 7.44 | 36 | 24.5 | 0.3 |
病例 | 血钾 | 血钠 | 血氯 | 血钙 | 血镁 | 血磷 | HCO3- |
---|---|---|---|---|---|---|---|
病例1 | 2.06 | 122 | 80.9 | 1.8 | 0.82 | 1.02 | 29.5 |
病例2 | 2.44 | 142.5 | 101.7 | 1.74 | 0.83 | 1.45 | 25 |
表22例Bartter综合征患儿血电解质水平检测结果(mmol/L)
病例 | 血钾 | 血钠 | 血氯 | 血钙 | 血镁 | 血磷 | HCO3- |
---|---|---|---|---|---|---|---|
病例1 | 2.06 | 122 | 80.9 | 1.8 | 0.82 | 1.02 | 29.5 |
病例2 | 2.44 | 142.5 | 101.7 | 1.74 | 0.83 | 1.45 | 25 |
基因型 | 基因 | 位置 | 编码产物 | OMIM | 遗传方式 |
---|---|---|---|---|---|
Ⅰ型 | SLC12A1 | 15q21.1 | NKCC2 | 601678 | AR |
Ⅱ型 | KCNJ1 | 11q24.3 | ROMK | 241200 | AR |
Ⅲ型 | CLCNKB | 1p36.13 | CLC-Kb | 607364 | AR |
Ⅳa型 | BSND | 1p32.3 | Barttin | 602522 | AR |
Ⅳb型 | CLCNKA | 1p36.13 | CLC-Ka | 602522 | DR |
CLCNKB | CLC-Kb | 613090 | |||
Ⅴ型 | CASR | 3q13.33 | CaSR | 601199 | AD |
表3BS的相关致病基因、分类和遗传方式[2]
基因型 | 基因 | 位置 | 编码产物 | OMIM | 遗传方式 |
---|---|---|---|---|---|
Ⅰ型 | SLC12A1 | 15q21.1 | NKCC2 | 601678 | AR |
Ⅱ型 | KCNJ1 | 11q24.3 | ROMK | 241200 | AR |
Ⅲ型 | CLCNKB | 1p36.13 | CLC-Kb | 607364 | AR |
Ⅳa型 | BSND | 1p32.3 | Barttin | 602522 | AR |
Ⅳb型 | CLCNKA | 1p36.13 | CLC-Ka | 602522 | DR |
CLCNKB | CLC-Kb | 613090 | |||
Ⅴ型 | CASR | 3q13.33 | CaSR | 601199 | AD |
1 | Bartter FC, Pronove P, Gill JR Jr, et al. Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. A new syndrome[J]. Am J Med, 1962, 33: 811. |
2 | Cunha TDS, Heilberg IP. Bartter syndrome: causes, diagnosis, and treatment[J]. Int J Nephrol Renovasc Dis, 2018, 11: 291. |
3 | 李雯. 儿童Bartter综合征: 26例单中心临床分析[D]. 杭州: 浙江大学, 2019. |
4 | Zhou J, Wang C, Bao H. [Progress of research on the role of CLCNKB gene in classical Bartter syndrome][J]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 2020, 37(5): 573. |
5 | 周嘉然, 王春莉, 鲍华英. CLCNKB基因在经典型Bartter综合征发病机制中的作用[J]. 中华医学遗传学杂志, 2020, 37(5): 573. |
6 | 韩婷婷, 王文红. 儿童遗传性肾小管碱中毒诊疗进展[J]. 临床儿科杂志, 2021, 39(2): 157. |
7 | Bignon Y, Sakhi I, Bitam S, et al. Analysis of CLCNKB mutations at dimer-interface, calcium-binding site, and pore reveals a variety of functional alterations in ClC-Kb channel leading to Bartter syndrome[J]. Hum Mutat, 2020, 41(4): 774. |
8 | Fahlke C, Fischer M. Physiology and pathophysiology of ClC-K/barttin channels[J]. Front Physiol, 2010, 1: 155. |
9 | Andrini O, Keck M, Briones R, et al. ClC-K chloride channels: emerging pathophysiology of Bartter syndrome type 3[J]. Am J Physiol Renal Physiol, 2015, 308(12): F1324. |
10 | 韩玥, 郎艳华, 林毅, 等. 42例3型巴特综合征CLCNKB基因变异分析和基因型/表型研究[J]. 中华肾脏病杂志, 2019, 35(7): 499. |
11 | García Castaño A, Pérez de Nanclares G, Madariaga L, et al. Poor phenotype-genotype association in a large series of patients with type Ⅲ Bartter syndrome[J]. PLoS One, 2017, 12(3): e0173581. |
12 | Seys E, Andrini O, Keck M, et al. Clinical and genetic spectrum of bartter syndrome type 3[J]. J Am Soc Nephrol, 2017, 28(8): 2540. |
13 | Konrad M, Nijenhuis T, Ariceta G, et al. Diagnosis and management of Bartter syndrome: executive summary of the consensus and recommendations from the European Rare Kidney Disease Reference Network Working Group for tubular disorders[J]. Kidney Int, 2021, 99(2): 324. |
14 | 中国研究型医院学会罕见病分会, 中国罕见病联盟, 北京罕见病诊疗与保障学会, 等. Gitelman综合征诊疗中国专家共识(2021版)[J]. 协和医学杂志, 2021, 12(6): 902. |
15 | Nuñez-Gonzalez L, Carrera N, Garcia-Gonzalez MA. Molecular basis, diagnostic challenges and therapeutic approaches of Bartter and Gitelman syndromes: a primer for clinicians[J]. Int J Mol Sci, 2021, 22(21): 11414. |
16 | Nascimento CL, Garcia CL, Schvartsman BG, et al. Treatment of Bartter syndrome. Unsolved issue[J]. J Pediatr (Rio J), 2014, 90(5): 512. |
17 | Oğuz SS, Gökmen T, Erdeve O, et al. Acetyl salicylic acid treatment in neonatal Bartter syndrome[J]. Pediatr Nephrol, 2011, 26(8): 1339. |
18 | Yang X, Zhang G, Wang M, et al. Bartter syndrome type 3: phenotype-genotype correlation and favorable response to ibuprofen[J]. Front Pediatr, 2018, 6: 153. |
19 | Gasongo G, Greenbaum LA, Niel O, et al. Effect of nonsteroidal anti-inflammatory drugs in children with Bartter syndrome[J]. Pediatr Nephrol, 2019, 34(4): 679. |
20 | Mazaheri M, Assadi F, Sadeghi-Bojd S. Adjunctive acetazolamide therapy for the treatment of Bartter syndrome[J]. Int Urol Nephrol, 2020, 52(1): 121. |
No related articles found! |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||